A prospective observational safety study of patients with <scp> <i>BRAF</i> <sup>V</sup> </scp> <sup>600</sup> ‐mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)Pippa Corrie, Piotr Rutkowski, Albert J. ten Tije et al.|British Journal of Dermatology|2018Cited by 4